Pulmonary fibrosis is a condition that causes lung scarring and stiffness. It develops when the alveoli, tiny air sacs that transfer oxygen to the blood, become damaged and inflamed. Body tries to heal the damage with scars, but these scars collapse the alveoli and make the lungs less elastic. Changes in the lungs can also increase the blood pressure in the pulmonary artery. This condition, called pulmonary hypertension, makes the heart work harder and it may fail.
In Norway the statistical analysis of pulmonary fibrosis was resulted as bromocriptine, cabergoline, pergolide, and ropinirole, but not pramipexole, have the potential for drug-drug interactions mediated by the cytochrome P450 (CYP) enzyme system. The occurrence of dyskinesia may be linked to stimulation of the dopamine D(1) receptor, for which cabergoline and pergolide have a similar and relatively high affinity; bromocriptine, pramipexole, and ropinirole have been associated with a lower risk of dyskinesias.